Seres Therapeutics (NASDAQ:MCRB – Get Free Report) and Aprea Therapeutics (NASDAQ:APRE – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.
Profitability
This table compares Seres Therapeutics and Aprea Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Seres Therapeutics | -1,192.94% | -114.82% | -34.15% |
| Aprea Therapeutics | -4,405.59% | -47.60% | -40.97% |
Valuation and Earnings
This table compares Seres Therapeutics and Aprea Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Seres Therapeutics | $790,000.00 | 63.73 | $5.70 million | ($2.43) | -2.06 |
| Aprea Therapeutics | $290,000.00 | 33.60 | -$12.60 million | ($1.08) | -0.72 |
Seres Therapeutics has higher revenue and earnings than Aprea Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Seres Therapeutics and Aprea Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Seres Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Aprea Therapeutics | 1 | 1 | 3 | 0 | 2.40 |
Seres Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 239.32%. Aprea Therapeutics has a consensus target price of $3.07, suggesting a potential upside of 296.21%. Given Aprea Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Seres Therapeutics.
Volatility & Risk
Seres Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.
Summary
Aprea Therapeutics beats Seres Therapeutics on 8 of the 14 factors compared between the two stocks.
About Seres Therapeutics
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
